Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Join SI Premium – FREE
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.59), $0.18 better than the analyst estimate of ($0.77).
For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- National Bank Holdings (NBHC) PT Lowered to $43 at DA Davidson
- Popular stocks option volume leaders: SPCX INTC MU AVGO MSTR CBRS SOFI NKE UBER CRWV
- Increasing unusual call option volume: PAGS GFL UMC BBD STNE ACB XP GEVO ITUB NXH DNA OPTT
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
